What question did this study set out to answer?

To determine whether patients with idiopathic pulmonary fibrosis and preserved lung volume benefit from nintedanib to the same extent as those with more severe lung volume impairment.

September 26, 2016ThoraxOpen Access

Nintedanib in patients with idiopathic pulmonary fibrosis and preserved lung volume

View Full Paper

Ask AI

Bookmark

To determine whether patients with idiopathic pulmonary fibrosis and preserved lung volume benefit from nintedanib to the same extent as those with more severe lung volume impairment.
Post hoc subgroup analysis of pooled data from two replicate phase III randomized trials (INPULSIS; NCT01335464 and NCT01335477).
Patients were stratified by baseline forced vital capacity (FVC) % predicted into preserved volume (>90%, n=274) and impaired volume (≤90%, n=787) cohorts receiving nintedanib or placebo.
Among placebo-treated patients, the adjusted annual rate of FVC decline was -224.6 mL/year in the FVC >90% predicted cohort and -223.6 mL/year in the FVC ≤90% predicted cohort.
With nintedanib, adjusted annual FVC decline was -91.5 mL/year in the >90% subgroup (difference vs placebo: 133.1 mL/year, 95% CI 68.0 to 198.2) and -121.5 mL/year in the ≤90% subgroup (difference vs placebo: 102.1 mL/year, 95% CI 61.9 to 142.3).
No statistically significant differences between subgroups were detected for annual FVC decline, St George's Respiratory Questionnaire score change, or time to first acute exacerbation.

Discussion

No takes yet. Share an insight, caveat, or question.

Implication

Randomized trial subgroup analysis reveals slowed lung function decline with nintedanib in preserved lung volume, highlighting the value of early intervention.

Cite This Study

Kolb et al. (2016) studied this question.

synapsesocial.com/papers/6a0f1fc704e2b0ba896c941d https://doi.org/10.1136/thoraxjnl-2016-208710

View Full Paper

Ask AI

Bookmark

Implication

Randomized trial subgroup analysis reveals slowed lung function decline with nintedanib in preserved lung volume, highlighting the value of early intervention.

Nintedanib in patients with idiopathic pulmonary fibrosis and preserved lung volume

Key Points

Discussion

Implication

Cite This Study

Nintedanib in patients with idiopathic pulmonary fibrosis and preserved lung volume

Key Points

Discussion

Implication

Cite This Study

Also Consider

Also Consider